イスラエル, テルアビブ
Ron Ram
24年の経験
- ロン・ラム医師は幹細胞移植手術を数百件執刀しており、この分野における卓越した技術を実証しています。
- スラスキー医療センター（イヒロフ）は年間40万人以上の患者を診療しており、その広範な医療提供能力と高い専門性を示しています。
- 費用に含まれるもの：入院、ホテル宿泊、病院への送迎。
- 滞在情報：病院21日間、ホテル14日間、費用に含まれます。
- 治療法：CAR T細胞療法。
| トルコ | オーストリア | スペイン | |
| CAR-T細胞療法 | から $150,000 | から $350,000 | から $330,000 |
BookimedはCAR-T細胞療法価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックでCAR-T細胞療法代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。CAR-T細胞療法で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。CAR-T細胞療法の旅路でお一人になることはありません。
Professor Omur Gokmen Sevindik, who completed a hematology fellowship at the Mayo Clinic, leads this treatment. The package costs approximately $200,000 – covering the entire 28-day inpatient cycle, all meals, and accommodation for one companion at the JCI-accredited Istanbul Florence Nightingale Hospital. This TÜV Hessen-certified smart hospital provides dedicated nursing and multi-language support. Patients should plan to stay in Istanbul for at least two months following discharge for monitoring.
This package provides personalized CAR-T cell dosing tailored to a patient's specific disease progression. Professor Ceyhun Bozkurt, a published SIOP/EBMT member with expertise in childhood blood disorders, leads the full-cycle management at Medical Park Bahcelievler Hospital. The approximate $300,000 fee covers a 28-day hospital stay in infection-controlled rooms with 24/7 monitoring. CAR-T cells are produced at the GMP-certified Acıbadem Labcell laboratory for safety. A bridge therapy option allows for continuous medical supervision prior to infusion if needed.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.